Alpha Cognition Inc (TSE:ACOG) has released an update.
Alpha Cognition Inc. has reached a pivotal success with the US Patent and Trademark Office’s Notice of Allowance for its Alzheimer’s drug, ZUNVEYL, which now has a patent life extending through 2042. This approval not only signifies the innovative breakthrough in their research but also amplifies the company’s capacity to secure its intellectual property in the lucrative United States market. ZUNVEYL is an FDA-approved medication aimed at treating mild to moderate Alzheimer’s disease, representing a new generation in acetylcholinesterase inhibition with fewer expected gastrointestinal side effects.
For further insights into TSE:ACOG stock, check out TipRanks’ Stock Analysis page.
